Board of Directors
Glenn Saldanha
Chairman and Managing Director, Glenmark Pharmaceuticals Limited
Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals, a USD 1.6 billion company with growing presence across more than 80 countries. A visionary leader, he has been instrumental in transforming Glenmark into a diversified, innovation-led pharmaceutical company recognized on the global stage.
Under his leadership, Glenmark has built strong capabilities in R&D, biologics, and specialty therapies, becoming one of the few Indian pharma companies with novel molecules in global clinical development. Through the company’s biotech arm, Ichnos Glenmark Innovation (IGI), he has enabled breakthrough research in oncology and immunology to reach patients worldwide, shaping India’s position on the global pharmaceutical innovation map.
Honoured with the EY Entrepreneur of the Year Award in 2017, Glenn is widely regarded as a thought leader in the pharmaceutical sector. He continues to champion accessible innovation, advanced manufacturing, and strategic global partnerships to deliver lasting value for patients and healthcare systems.
A pharmacy graduate from Mumbai University and an MBA from NYU’s Leonard Stern School of Business, he brings a unique blend of scientific acumen and strategic foresight, strengthened by his early experiences at Eli Lilly and PwC in the U.S.
Cyril Konto, M.D.
President, Executive Director and Chief Executive Officer, IGI
Cyril Konto is responsible for the overall management at IGI. He joined Ichnos as Chief Medical Officer and has served as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies. At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. Cyril began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
Dennis Purcell
Founder and Former Senior Managing Partner, Aisling Capital
Dennis Purcell is the original founder of Aisling Capital LLC and currently serves as a senior advisor. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for more than five years. While at H&Q, he was directly involved with more than two hundred completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld Today and other industry publications cited H&Q as the leading underwriter of life sciences securities.
Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. He is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering & Biotechnology News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen, and cited as one of the top 100 contributors to the biotechnology industry. Dennis received his master’s degree in business administration from Harvard Business School and his bachelor’s degree in accounting from the University of Delaware.
Lawrence Olanoff, M.D., Ph.D.
Former President and Chief Operating Officer, Forest Laboratories
Lawrence Olanoff is currently an adjunct assistant professor and special advisor to the President for Corporate Relations at the Medical University of South Carolina. Previously, he served as President and Chief Operating Officer for Forest Laboratories, Inc. from 2006 through 2010. From 2005 to 2006, Lawrence was Chief Executive Officer of Celsion Corporation. He also served as Executive Vice President of Research and Development and Chief Scientific Officer of Forest from 1995 to 2005. Prior to joining Forest, Lawrence served in senior clinical research roles at Sandoz Pharmaceutical Corporation and at The Upjohn Company.
During his pharmaceutical development career, Lawrence made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He serves as a member of the Board of Ironwood Pharmaceuticals as well as several nonprofit organizations.
Lawrence also held past directorships on the Boards of Forest Laboratories, Axovant Sciences Ltd., and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of South Carolina, and is the author of some forty scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism, and clinical toxicology.
Alind Sharma
Chief Human Resources Officer, Glenmark Pharmaceuticals Limited
Alind Sharma is President and Chief Human Resources Officer of Glenmark Pharmaceuticals Limited. He is responsible for driving organizational advancement through effective human capital strategy. His areas of focus comprise enriching and developing the organization’s diverse talent, appropriate and timely rewards through robust performance management, leadership development and talent engagement.
Previously, Alind served as Vice President of Human Capital at Optum, a part of the United Health Group. He is a graduate of the Indian Institute of Management in Ahmedabad, India.
Anurag Mantri
Executive Director and Global Chief Financial Officer, Glenmark Pharmaceuticals Limited
Anurag Mantri is the Executive Director and Global Chief Financial Officer of Glenmark Pharmaceuticals. With over three decades of multifaceted experience, Anurag exemplifies the strength to blend strategic vision with operational discipline and has built future-ready, digitally driven institutions across industries.
He is a proven change-maker known for driving large-scale business turnarounds, crafting innovative, growth-focused capital strategies, and enabling governance-led value creation across complex, high-impact environments.
A recipient of the Forbes India New Age CFO recognition, he is also a respected voice at leading forums on business transformation, automation & digitization, ESG, and corporate governance.
Anurag is a Chartered Accountant and holds a Bachelor’s degree in Commerce from the University of Rajasthan. Anurag’s career spans both multinationals and high-growth Indian enterprises, having held senior leadership roles at Schneider Electric, Cairn plc, HCL Tech, SRF, and L&T. Prior to joining Glenmark, he served on the Board of Jindal Stainless as Executive Director & Group CFO, where he led one of India’s most recognized corporate transformations.
With his profound expertise in strategic leadership, enterprise transformation, and financial excellence, Anurag continues to drive Glenmark’s global finance, corporate affairs, and governance.
Ms. Patricia Andrews
Independent Director on Glenmark and IGI Boards
Ms. Andrews is an accomplished biopharmaceutical executive and public company board member with a track record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations, and business development. Ms. Andrews previously served as Chief Executive Officer for Sumitomo Pharma Oncology, Inc. (SMP Oncology), where she led the organization through the integration of its multiple predecessor companies. Under her leadership, the organization completed three Phase 3 trials and expanded the clinical pipeline from two programs to eight. Prior to SMP Oncology, Ms. Andrews served as Chief Commercial Officer for Incyte and led the organization through the launch preparations and introduction of Jakafi®, the company’s first commercial product, a novel, first-in-class, first-in-disease agent for the treatment of myelofibrosis. While with Incyte, she also steered landmark licensing arrangements with Novartis and Eli Lilly that were critically important to fund the company’s long-term trajectory.
Prior to Incyte, Ms. Andrews spent 17 years with Pfizer, ultimately serving as Vice President and General Manager of the U.S. Oncology Business Unit, a $900 million portfolio at the time. Under her leadership, Sutent® was launched, becoming the market leader in renal cell carcinoma, and a refreshed positioning of Camptosar® led to robust revenue growth after years of declining sales in colorectal cancer. Ms. Andrews is a member of the Boston chapter of the Board of Advisors for Life Science Cares, a collective impact organization dedicated to fighting poverty in local communities. She earned an MBA from the University of Michigan and her BA from Brown University.
Ms. Andrews was the CEO of Sumitomo Pharma Oncology, Inc., a clinical-stage research and development biopharmaceutical company, and Global Head of Oncology and an Executive Officer for Sumitomo Pharma Co., Ltd. from 2017 to 2023. Prior to joining this organization in 2013, she was Executive Vice President and Chief Commercial Officer at Incyte for four years, where she established the commercial organization and launched its first-in-class, first-in-disease oncology product Jakafi®. She was also responsible for business development and completed multiple significant product licensing deals for Incyte. Ms. Andrews held increasing leadership positions at Pfizer from 1991-2008, with her final role being Vice President and General Manager of the U.S. Oncology Business Unit. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.